ODS Exam Prep - Casefinding and Solid Tumor Rules Vocabulary

Vocabulary flashcards covering core casefinding terminology, reporting requirements, and solid tumor rules from the lecture.

Casefinding

The process covering a range of cases that need to be assessed to determine whether or not they are reportable, with the goal of identifying every patient with a reportable cancer.

Reportable List

A document that identifies the types of cases to be included in the cancer registry database based on criteria set by governing agencies.

Class of Case

A classification assigned to accessioned cases based on the nature of involvement of the reporting facility in the care of the patient.

Analytic Cases

Cases diagnosed and/or administered any first course of treatment at the accessioning registry after the registry's reference date.

Non-Analytic Cases

Cases not required by the CoC and normally excluded from routine treatment or survival statistics, involving patients where the facility had limited or non-primary involvement.

First Course of Treatment

All methods of treatment recorded in the treatment plan and administered to the patient before disease progression or recurrence.

Timing Principle

A rule stating that if there is no treatment plan, established protocol, or management guidelines, initial treatment must begin within four months of the date of initial diagnosis.

Active Casefinding

A casefinding method where registry staff directly review source documents like pathology reports and disease indexes; it is thorough but time-consuming.

Passive Casefinding

A casefinding method relying on other departments to report cases; it is faster but carries a risk that cases may be missed.

Suspense File

A list of potentially reportable cases generated by combining multiple casefinding sources, containing a minimum set of data items.

Solid Tumor Rules

Rules effective for cases diagnosed 1/1/2018 and forward (replacing 2007 MP/H rules) used to assign topography, morphology, and behavior for solid tumors, excluding lymphoma and leukemia.

Clinically Disease-Free

A status indicating no evidence of disease (NED) on follow-up, used in timing rules to calculate time intervals between tumor diagnoses.